Applied DNA Sciences - APDN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $7.00
  • Forecasted Upside: 94.44 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.60
▼ -0.11 (-2.96%)

This chart shows the closing price for APDN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Applied DNA Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APDN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APDN

Analyst Price Target is $7.00
▲ +94.44% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Applied DNA Sciences in the last 3 months. The average price target is $7.00, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 94.44% upside from the last price of $3.60.

This chart shows the closing price for APDN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Applied DNA Sciences. This rating has held steady since April 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022HC WainwrightBoost Target$8.00Low
5/16/2022HC WainwrightLower TargetNA$6.00 ➝ $4.00Low
2/14/2022Maxim GroupLower Target$18.00 ➝ $6.00Low
2/11/2022HC WainwrightLower TargetBuy$8.00 ➝ $6.00High
12/10/2021HC WainwrightLower TargetBuy$11.00 ➝ $8.00High
11/30/2021HC WainwrightUpgradeBuy$11.00Low
10/13/2021HC WainwrightReiterated RatingBuy$11.00Low
8/13/2021HC WainwrightLower TargetBuy$13.00 ➝ $11.00High
5/14/2021Maxim GroupReiterated RatingBuy$18.00Low
4/22/2021HC WainwrightLower TargetBuy$14.00 ➝ $13.00Low
2/12/2021Roth CapitalInitiated CoverageBuy$24.00Low
1/11/2021HC WainwrightReiterated RatingReduce ➝ Buy$18.00 ➝ $14.00Medium
12/18/2020HC WainwrightLower TargetBuy$20.00 ➝ $12.00Medium
11/30/2020HC WainwrightLower TargetBuy$22.00 ➝ $20.00Medium
8/18/2020HC WainwrightReiterated RatingBuy$22.00Low
8/11/2020Maxim GroupReiterated RatingBuyHigh
7/31/2020Maxim GroupReiterated RatingBuy$21.00Low
7/20/2020HC WainwrightReiterated RatingBuy$18.00 ➝ $22.00Low
7/17/2020Maxim GroupReiterated RatingBuy$21.00Medium
7/2/2020HC WainwrightInitiated CoverageBuy$18.00High
5/15/2020Maxim GroupReiterated RatingBuy$21.00Low
5/5/2020Maxim GroupBoost TargetBuy$8.00 ➝ $18.00High
4/17/2020Maxim GroupReiterated RatingBuy$8.00Low
3/20/2020Maxim GroupReiterated RatingBuy$8.00High
12/13/2019Maxim GroupReiterated RatingBuy$8.00Low
12/4/2019Maxim GroupReiterated RatingBuy$8.00Low
11/22/2019Maxim GroupUpgradeHold ➝ Buy$8.00High
6/12/2019Maxim GroupReiterated RatingHoldLow
12/31/2018Maxim GroupDowngradeBuy ➝ HoldMedium
8/15/2018Maxim GroupLower TargetBuy ➝ Buy$5.00 ➝ $3.00High
4/24/2018Maxim GroupReiterated RatingBuy$5.00High
4/6/2018Maxim GroupSet TargetBuy$5.00High
2/9/2018Maxim GroupSet TargetBuy$5.00High
12/8/2017Maxim GroupSet TargetBuy$5.00Medium
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
2/19/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/19/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Applied DNA Sciences logo
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Read More

Today's Range

Now: $3.60
Low: $3.33
High: $3.73

50 Day Range

MA: $1.72
Low: $0.68
High: $5.83

52 Week Range

Now: $3.60
Low: $0.62
High: $7.35

Volume

1,940,402 shs

Average Volume

21,345,350 shs

Market Capitalization

$43.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Applied DNA Sciences?

The following sell-side analysts have issued reports on Applied DNA Sciences in the last twelve months: HC Wainwright, and Maxim Group.
View the latest analyst ratings for APDN.

What is the current price target for Applied DNA Sciences?

2 Wall Street analysts have set twelve-month price targets for Applied DNA Sciences in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 94.4%. HC Wainwright has the highest price target set, predicting APDN will reach $8.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for Applied DNA Sciences in the next year.
View the latest price targets for APDN.

What is the current consensus analyst rating for Applied DNA Sciences?

Applied DNA Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for APDN.

What other companies compete with Applied DNA Sciences?

How do I contact Applied DNA Sciences' investor relations team?

Applied DNA Sciences' physical mailing address is 50 HEALTH SCIENCES DRIVE, STONY BROOK NY, 11790. The technology company's listed phone number is (631) 240-8800 and its investor relations email address is [email protected] The official website for Applied DNA Sciences is www.adnas.com. Learn More about contacing Applied DNA Sciences investor relations.